[#item_full_content]
CANTON, Mass.–(BUSINESS WIRE)– #BKV–Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus infections are a major cause of complications in transplant patients, with no approved treatments. The company is pioneering an oral therapy that addresses the full spectrum of BK infection, from early reactivation thr